Gracell Biotechnologies Inc. (GRCL) Tops Q4 EPS by 2c

Gracell Biotechnologies Inc. (NASDAQ: GRCL) reported Q4 EPS of ($0.06), $0.02 better than the analyst estimate of ($0.08).

For earnings history and earnings-related data on Gracell Biotechnologies Inc. (GRCL) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79